Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amicidin-β Topical Solution in Contaminated or Infected Wounds or Abscesses
NCT07379684Phase 1Recruiting
- Sponsor
- Macro Biologics
- Start
- Aug 2026
- Primary completion
- Feb 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Amicidin-β in surgical site infection (SSI), post-traumatic wound infection and cutaneous abscess (4 arms), sponsored by Macro Biologics. Primary endpoint: Treatment Emergent Adverse Events. Started Aug 2026; status: recruiting.
02
Drugs
Amicidin-β
03
Conditions
surgical site infection (SSI)post-traumatic wound infectioncutaneous abscess
Beyond the preview
Go deeper on NCT07379684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07379684.